Abstract
A radioimmunoassay (RIA) for cytosine arabinoside (AraC) has been developed using antiserum raised in a sheep to an AraC monophosphate-ovalbumin conjugate. The antibody shows only 0.008% cross-reactivity with uracil arabinoside (AraU) and low (0.023%) cross-reactivity with other commonly co-administered drugs such as cytotoxic and antibacterial agents, and also a number of naturally occurring nucleosides and nucleotides. It does however cross-react by 125% with AraC monophosphate and by 109% with AraC triphosphate. As little as 1 ng/ml of AraC can be detected in plasma, serum, urine and cerebrospinal fluid (CSF) with no need for prior extraction. This RIA has been used to follow the disappearance of AraC from the plasma of patients receiving the drug.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Piall, E., Aherne, G. & Marks, V. A radioimmunoassay for cytosine arabinoside. Br J Cancer 40, 548–556 (1979). https://doi.org/10.1038/bjc.1979.220
Issue Date:
DOI: https://doi.org/10.1038/bjc.1979.220
This article is cited by
-
HPLC in biopharmaceutical investigations of drugs representing pyrimidine derivatives (A review)
Pharmaceutical Chemistry Journal (2007)
-
Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a Cancer and Leukemia Group B study
Cancer Chemotherapy and Pharmacology (1995)
-
Increase in Ara-C sensitivity in Ara-C sensitive and -resistant leukemia by stimulation of the salvage and inhibition of the de novo pathway
Annals of Hematology (1992)
-
Pharmacokinetics of ara-C and ara-U in plasma and CSF after high-dose administration of cytosine arabinoside
Cancer Chemotherapy and Pharmacology (1992)
-
Phenotypic analysis of 1-B-d-arabinofuranosylcytosine deamination in patients treated with high doses and correlation with response
Cancer Chemotherapy and Pharmacology (1992)